Studies have found that the reduction of AMPK activity is an important pathological feature of NAFLD, and targeted activation of the AMPK signaling pathway can significantly improve liver lipid metabolism disorders and related pathological injuries (Figure 3). This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatotic liver disease.